Medivation Reaches New 52-Week High (MDVN)

NEW YORK ( TheStreet) -- Medivation (Nasdaq: MDVN) hit a new 52-week high Tuesday as it is currently trading at $96.44, above its previous 52-week high of $96.16 with 16,038 shares traded as of 9:39 a.m. ET. Average volume has been 730,400 shares over the past 30 days.

Medivation has a market cap of $3.44 billion and is part of the health care sector and drugs industry. Shares are up 105.8% year to date as of the close of trading on Monday.

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including poor profit margins, weak operating cash flow and generally poor debt management. You can view the full Medivation Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit

General Motors Spikes on Report It's Considering Listing Shares of Cruise Unit